Venous Thromboembolism | Pharmacor | G7 | 2015
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant public health and financial burden. The expansion of the treatment labels of the four nonmonitored, fixed-dose, oral anticoagulants into the treatment and secondary prophylaxis of VTE is addressing the need for more-convenient alternatives to current standards of care; and these agents will drive market growth during the forecast period. However, opportunities remain in other underserved VTE indications, including primary prophylaxis of VTE in acute medically ill and ambulatory cancer patients.
Related Market Assessment Reports
Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
Report
Diabetic Macular Edema / Diabetic Retinopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Macular Edema (US)
Diabetic macular edema (DME) is a serious complication of diabetic retinopathy caused by persistently elevated blood glucose levels. Without timely treatment, DME can progress to significant vision…
Report
Multiple System Atrophy – Unmet Need – Multiple System Atrophy (US/EU) – Unmet Need – Multiple System Atrophy (US/EU)
Multiple system atrophy (MSA) is a rare, rapidly progressing neurodegenerative synucleinopathy that disrupts movement, balance, and autonomic function. Current management comprises only symptomatic…
Report
Atopic Dermatitis / Atopic Eczema – Current Treatment – Treatment Algorithms: Claims Data Analysis – Atopic Dermatitis (Pediatric) (US)
Atopic dermatitis (AD) is a chronic, itchy, inflammatory skin disease often starting in childhood. It is usually treated with topical immunotherapy. Refractory cases may need systemic…
